Payers growing influence on R&D decision making

@article{Hughes2008PayersGI,
  title={Payers growing influence on R\&D decision making},
  author={Bethan Hughes},
  journal={Nature Reviews Drug Discovery},
  year={2008},
  volume={7},
  pages={876-878}
}
  • Bethan Hughes
  • Published 1 November 2008
  • Medicine
  • Nature Reviews Drug Discovery
A recent report from the European Commission highlights the increasing importance of payer considerations in demonstrating product value through clinical development programmes. 
Reflections on the evolution of health technology assessment in Europe
TLDR
How HTA has evolved over time as well as its impact on policy and practice in Europe over the last decade is explored, with a focus on England, France, Germany and Sweden.
Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
TLDR
Investing in CER can help address the current gap in publicly available, credible, up-to-date, and scientifically based comparative information on the effectiveness of drugs and other health interventions, thereby facilitating access to and public and private investment in the most beneficial new drugs and technologies.
Comparative effectiveness research and evidence-based health policy: experience from four countries.
CONTEXT The discussion about improving the efficiency, quality, and long-term sustainability of the U.S. health care system is increasingly focusing on the need to provide better evidence for
Toward effective health technology regulation
TLDR
The thesis demonstrates that attaining good health technology regulation is complex and challenging, because of the inherent uncertainty regarding the benefits and risks of new technologies, their growing diversity and complexity, the limitations of existing study designs and assessment methods, and the increased demands placed on regulators to meet sometimes conflicting objectives.
Benefit–risk assessment: the use of clinical utility index
  • D. Ouellet
  • Psychology
    Expert opinion on drug safety
  • 2010
TLDR
The use of a clinical utility index (CUI) for quantitative assessment of benefit/risk is most useful when there are multiple attributes involved in a decision to better understand the relevance of each attribute and when differentiation from competitors is critical to the success of a compound.
A Theoretical Evidence: The Mediating Role Of Creativity On The Relationship Between Knowledge Management And Entrepreneurial Orientation Toward Innovation Performance In The Jordanian Smes
This research paper explored the importance of innovation performance in the Jordanian SMEs industry, according to the signif icant impact of the industry on the economy worldwide. Mainly, the most
Teacher counselors’ and pupils’ perceptions of correctional strategies used by teachers and their impact on pupils' socio-emotional development in primary schools in Kericho County, Kenya
The issue of pupils‘ correction in primary schools is perceived as an intricate affair that requires well designed and thought out approaches in order to ensure pupils‘ proper socio-emotional
...
...